Salt la conţinut

Drepanocitoză (pediatrie)

Managementul anemiei

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (se deschide o fereastră nouă)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Sursă‎: Lancet Haematol. 2023 ;10(4):e261-71.

Index‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (se deschide o fereastră nouă)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (se deschide o fereastră nouă)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Sursă‎: Acta Haematol 1995;94(3):128-34.

Index‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (se deschide o fereastră nouă)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (se deschide o fereastră nouă)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Sursă‎: Haematologica 2006;91(8):1076-83.

Index‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (se deschide o fereastră nouă)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (se deschide o fereastră nouă)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Sursă‎: J Obstet Gynaecol 2007;27(1):82-3.

Index‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (se deschide o fereastră nouă)